Lipid comprising polyunsaturated fatty acids

Patent metadata

Field	Value
Publication number	US-10335386-B2
Application number	US-201615373145-A
Country	US
Kind code	B2
Filing date	Dec 8, 2016
Priority date	Jun 15, 2012
Publication date	Jul 2, 2019
Grant date	Jul 2, 2019

Abstract

The present invention relates to extracted plant lipid, comprising fatty acids in an esterified form.

First claim

The invention claimed is:

1. Canola oil extracted from Brassica napus seed, comprising a total fatty acid content which comprises docosahexaenoic acid (DHA, 22:6ω3), wherein the DHA is present at a level of between 7% and 20% of the total fatty acid content, wherein at least 70% of the DHA in the total fatty acid content is esterified at the sn-1 or sn-3 position of triacylglycerol (TAG) in the canola oil.

2. The canola oil of claim 1 , comprising docosapentaenoic acid (DPA, 22:5ω3), wherein the DPA is present at a level of less than 4% of the total fatty acid content.

3. The canola oil of claim 1 , comprising a total saturated fatty acid content which comprises palmitic acid and, if present, myristic acid (C14:0), wherein the palmitic acid is present at a level of between 2% and 16% of the total fatty acid content and the myristic acid, if present, is present at a level of less than 1% of the total fatty acid content.

4. The canola oil of claim 1 , wherein a sum total of arachidonic acid (ARA), eicosapentaenoic acid (EPA), DPA and DHA is present of between 7% and 25% of the total fatty acid content.

5. The canola oil of claim 1 , comprising one or more of campesterol, Δ5-stigmasterol, eburicol, β-sitosterol, Δ5-avenasterol, Δ7-stigmasterol and Δ7-avenasterol.

6. The canola oil of claim 1 , wherein a level of α-linolenic acid (ALA) between 7% and 40% is present in the total fatty acid content of the canola oil.

7. The canola oil of claim 1 , wherein a level of GLA of less than 4% is present in the total fatty acid content of the canola oil.

8. The canola oil of claim 1 , wherein a level of SDA between 0.05% and 7% is present in the total fatty acid content of the canola oil.

9. The canola oil of claim 1 , wherein a level of ETA between 0.05% and 4% is present in the total fatty acid content of the canola oil.

10. The canola oil of claim 1 , wherein a level of DPA between 0.05% and 8% is present in the total fatty acid content of the canola oil.

11. The canola oil of claim 3 , wherein the total saturated fatty acid content in the canola oil is between 4% and 20% of the total fatty acid content.

12. The canola oil of claim 1 , wherein a total monounsaturated fatty acid content of between 4% and 35% is present in the total fatty acid content of the canola oil.

13. The canola oil of claim 1 , comprising a total polyunsaturated fatty acid content of between 20% and 75% of the total fatty acid content.

14. The canola oil of claim 1 , comprising new ω3 fatty acids in a total ω3 fatty acid content, wherein the level of new ω3 fatty acids in the canola oil is between 9% and 33% of the total fatty acid content.

15. The canola oil of claim 1 , wherein at least 80% of the DHA esterified in the form of TAG is in the sn-1 or sn-3 position of the TAG.

16. The canola oil of claim 1 , wherein the canola oil comprises tri-DHA TAG (TAG 66:18).

17. The canola oil of claim 1 , wherein a level of about 1% C20:1 is present in the total fatty acid content in the canola oil.

18. The canola oil of claim 1 , wherein a level of eicosatrienoic acid (ETrA) between 0.05% and 2% is present in the total fatty acid content of the canola oil.

Assignees

• Commw Scient Ind Res Org
• Grains Res & Dev Corp
• Nuseed Pty Ltd

Inventors

• Petrie James Robertson
• Singh Surinder Pal
• De Feyter Robert Charles

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title